biostudies-literatureMarek RDNCI NIH HHSZCHNIH HHS1273https://www.ebi.ac.uk/biostudies/studies/S-EPMC11599078biostudies-literatureUnknown12(11)<b>Background/Objectives</b>: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target this axis, many of these fail due to the emergent expression of AR RNA splice variants, such as AR-V7, that can signal independently of ligand binding. Other therapies, such as vaccination against prostate-specific antigens, have achieved FDA approvals but have fallen short of being incorporated as standard-of-care therapies for advanced prostate cancer. This may be due to the elevated level of immunosuppression observed in prostate cancer, which remains largely refractory to immune checkpoint blockade. <b>Methods</b>: We developed a VaccinesVaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.PMC115990785T32-CA009111-45T32 CA0091115R01-CA238211R21CA274044-01R21 CA274044Trotter TNChen MHalabi SLei GYang XMarek RDHartman ZCWang MEWang TLyerly HKMcBane JLiu CWei JfalseVaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.<b>Background/Objectives</b>: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target this axis, many of these fail due to the emergent expression of AR RNA splice variants, such as AR-V7, that can signal independently of ligand binding. Other therapies, such as vaccination against prostate-specific antigens, have achieved FDA approvals but have fallen short of being incorporated as standard-of-care therapies for advanced prostate cancer. This may be due to the elevated level of immunosuppression observed in prostate cancer, which remains largely refractory to immune checkpoint blockade. <b>Methods</b>: We developed a 2024-01-01T00:00:00Z2024 Nov2025-04-19T17:35:04.151Z2025-04-19T17:35:04.151ZS-EPMC115990783959117610.3390/vaccines12111273